Tuberous Sclerosis Complex Clinical Trial
Official title:
Tuberous Sclerosis Complex and Lymphangioleiomyomatosis Pregnancy Registry
This study is an observational registry designed to gather information about Tuberous Sclerosis Complex (TSC) and Lymphangioleiomyomatosis (LAM) in pregnant women and their child.
Tuberous sclerosis complex (TSC) is caused by mutations in tuberous sclerosis complex 1 (TSC 1) and tuberous sclerosis complex 2 (TSC 2) leading to overactivation of the mammilian target of rapamycin (mTOR) pathway resulting in multiorgan disease. Specifically, patients are at risk for autism, epilepsy, intellectual disability, renal cysts, tuberous sclerosis associated neuropsychiatric disorder (TAND), lymphangioleiomyomatosis (LAM), and benign tumors throughout the body including subependymal giant cell astrocytomas (SEGAs), renal and liver angiomyolipomas (AMLs), and cardiac rhabdomyomas (rhabdomyomas). Sporadic LAM occurs mostly in women and many patients with LAM have TSC gene mutations. The purpose of this study is to gather information to help clinicians develop evidence-based guidance for the care of TSC and LAM patients during pregnancy and to provide screening recommendations for fetal TSC. Participants will be asked to complete monthly online surveys screening for changes in the pregnancy, maternal health/medication changes, and other care. For infants enrolled after birth, clinical data will be collected and reviewed for up to 5 years of age. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04595513 -
Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants
|
Phase 1/Phase 2 | |
| Completed |
NCT02687633 -
Early Behavioral Intervention to Improve Social Communication Function in Infants With Tuberous Sclerosis Complex
|
N/A | |
| Completed |
NCT02201212 -
Everolimus for Cancer With TSC1 or TSC2 Mutation
|
Phase 2 | |
| Completed |
NCT01767779 -
Potential EEG Biomarkers and Antiepileptogenic Strategies for Epilepsy in TSC
|
||
| Recruiting |
NCT05104983 -
Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study
|
Phase 2 | |
| Recruiting |
NCT02098759 -
Long-term, Prospective Study Evaluating Clinical and Molecular Biomarkers of Epileptogenesis in a Genetic Model of Epilepsy - Tuberous Sclerosis Complex
|
N/A | |
| Recruiting |
NCT01730209 -
Efficacy of RAD001/Everolimus in Autism and NeuroPsychological Deficits in Children With Tuberous Sclerosis Complex
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03356769 -
Aspirin as an add-on Treatment of Refractory Epilepsy in Tuberous Sclerosis Complex
|
Phase 2 | |
| Recruiting |
NCT04987463 -
Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in Infants
|
Phase 2/Phase 3 | |
| Completed |
NCT05323370 -
Lymphangioleiomyomatosis, a Study on Cathepsin K
|
||
| Recruiting |
NCT06392009 -
A Study of Radiprodil on Safety, Tolerability, Pharmacokinetics, and Effect on Seizures and Behavioral Symptoms in Patients With TSC or FCD Type II
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05604170 -
Open-label Study of Adjunctive GNX Treatment in Children and Adults With TSC-related Epilepsy
|
Phase 3 | |
| Completed |
NCT03276195 -
Studies in Patients With Tuberous Sclerosis Complex
|
||
| Recruiting |
NCT05059327 -
Basimglurant in Children, Adolescents, and Young Adults With TSC
|
Phase 2 | |
| Completed |
NCT02061397 -
Safety of Simvastatin in LAM and TSC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04112537 -
Dermatologic Patterns of Tuberous Sclerosis Patients and Somatic Mutation Relationship
|
||
| Active, not recruiting |
NCT02962414 -
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
|
Phase 3 | |
| Active, not recruiting |
NCT05495425 -
Clinical Study of NPC-12Y Gel in Patients With Skin Lesions Associated With TSC
|
Phase 3 | |
| Active, not recruiting |
NCT05044819 -
Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
|
Phase 4 | |
| Completed |
NCT01929642 -
Rapalogues for Autism Phenotype in TSC: A Feasibility Study
|
Phase 2 |